In the third quarter, more than 80 Chinese new drug research and development companies completed financing, 50% of which was early stage financing

In the just-concluded third quarter of 2021, China's new drug R&D field (excluding in vitro diagnostics and testing, CRO, etc.
) financing is still active
.

According to incomplete statistics, more than 80 companies completed different rounds and types of financing in the third quarter, of which early financing (round A+ and before) accounted for the largest proportion

50% is early stage financing, cell therapy and gene editing are favored

50% is early stage financing, cell therapy and gene editing are favored

Among the 86 financing cases we counted, 43 cases of early financing (round A+ and before) accounted for as high as 50%
.

Among them, there were 6 angel rounds and angel+ rounds, 8 pre-A rounds of financing, and 26 A rounds and A+ rounds

As we all know, 2021 is the first year of the commercialization of CAR-T cells in China.
Two CAR-T products from Fosun Kate and WuXi Junuo have been approved for the market, bringing confidence to the development of treatments in this field
.

In the third quarter of this year, the newly established Xingyiang Biotechnology completed a $40 million angel round of financing led by Eli Lilly Asia Fund.

In terms of gene editing, gene editing technology represented by CRISPR has shined in recent years.
Not only has it won the Nobel Prize in Chemistry, it has also been listed as an important scientific breakthrough in 2020 by "Science" magazine, and related therapies have made considerable progress in clinical aspects
.

The company in the third quarter, the number of dedicated editors gene therapy have also completed early financing, such as bass Angke, sharp positive genes, gene sprouts, refine biology

In addition, some companies are tapping the potential of new dosage forms, and new transdermal drug delivery is one of them
.

Transdermal administration refers to a new dosage form that is administered on the surface of the skin, passes through the skin, and enters the systemic circulation to produce systemic or local therapeutic effects

New technologies such as mRNA and protein liquid-liquid separation have emerged

New technologies such as mRNA and protein liquid-liquid separation have emerged

Among the 86 financing cases we have counted, 35 cases are financing round B and above (excluding cases where financing rounds are not disclosed)
.

Among them, the financing amount of many companies such as Fonogym Bio, Biot Bioscience, Real Bio, Abbio, Reindeer Medical, Arnold Pharmaceuticals, Yaojie Ankang, and Shengnuo Pharmaceutical have reached nearly 100 million US dollars or more

In particular, it is worth mentioning that Abbio, which focuses on the research and development of mRNA drugs, has completed more than US$700 million in Series C financing jointly led by Temasek, Invesco Development Market Fund, and Zhengxingu Capital
.

As a matter of fact, as many new mRNA vaccines around the world have made breakthroughs one after another, mRNA technology is being favored by more and more people

In addition to mRNA, tumors and autoimmune diseases are still the two main research directions
.

For example, Xinkanghe Biology, Lingke Pharmaceutical, Jiayue Pharmaceutical, and Yaoxin Biology all have R&D activities in these two fields, while Zhengtengkang Biology, Zanrong Pharmaceutical, and Arnold Pharmaceutical are dedicated to the development of cancer treatment drugs.

In addition, we have also observed that some biomedical companies focusing on innovative therapies/technologies have received capital support
.
For example, Yituo Pharmaceutical, which built an innovative protein liquid-liquid phase separation technology platform to efficiently target "untargetable" drug targets, completed the B round of financing; Shengnuo Pharmaceutical, which focuses on the application of nucleic acid interference technology (RNAi) for the creation of new drugs, Completed US$105 million in Series E financing; Suunuo Bio, which focuses on the development of a molecular chaperone-mediated protein degradation technology platform, completed more than US$40 million in Series B financing
.

other

other

In addition to the above companies, Force Life, Beihai Biological, Boan Biological, Saiyuan Biological, Shentuo Biological, Xihu Biological, etc.
have completed a new round of financing in the third quarter
.
Among them, Changtai Pharmaceutical, which focuses on the field of respiratory and mental diseases, has successively completed hundreds of millions of yuan in round B financing and hundreds of millions in round B+ financing
.

At the same time, some companies have successfully IPOs on the Hong Kong Stock Exchange or the Science and Technology Innovation Board
.
Among them, Connoa Biotech and Tengshengbo Pharmaceutical have been listed on the Hong Kong Stock Exchange.
The former focuses on independent discovery and development of innovative biological therapies in the field of autoimmunity and tumor treatment, and the latter is committed to breakthrough innovations in response to infectious diseases represented by The severe public health disease challenge
.
Jindike Biology and Yizhong Pharmaceutical have been listed on the Science and Technology Innovation Board successively.
The former focuses on the research and development, production and sales of human vaccines, and the latter is dedicated to the research and development and industrialization of new and improved anti-tumor drugs
.

In addition, in the third quarter, Shengnuo Pharmaceutical, Tianguangshi Biotechnology, Beihai Kangcheng, Sizhidi Pharmaceutical, and Ruike Biotechnology have all submitted IPO applications on the Hong Kong Stock Exchange
.
On the Science and Technology Innovation Board, companies such as Pego Biotech and Nuocheng Jianhua have submitted IPOs
.
Due to space limitations, I will not introduce them one by one here
.

Reference materials:

Reference materials:

[1] Xingyiang Biotechnology completed an angel round of financing of 40 million US dollars, committed to the development of NK new technology platform and products.
Retrieved July 30.
2021.
from https:// Xingyiang Biotechnology completed an angel round of financing of 40 million US dollars, committed to the development of NK new technology platform and products.
Retrieved July 30.
2021.
from https:// [2] Aibo Biosciences completed more than US$700 million in Series C financing to accelerate the deployment of the mRNA platform in multiple vaccines and therapeutic fields.
Retrieved Aug 19.
2021.
from https://mp.
weixin.
qq.
com/s/FkRQVqAQwfueTWOnmBIT9w

[2] Aibo Biosciences completed more than US$700 million in Series C financing to accelerate the deployment of the mRNA platform in multiple vaccines and therapeutic fields.
Retrieved Aug 19.
2021.
from https://mp.
weixin.
qq.
com/s/FkRQVqAQwfueTWOnmBIT9w

[3] Press releases and public information of various companies

[3] Press releases and public information of various companies